Literature DB >> 12960974

Widespread distribution of beta-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol.

C Bourgoin1, C Emiliani, E J Kremer, A Gelot, B Tancini, R A Gravel, C Drugan, A Orlacchio, L Poenaru, C Caillaud.   

Abstract

Sandhoff disease is a severe inherited neurodegenerative disorder resulting from deficiency of the beta-subunit of hexosaminidases A and B, lysosomal hydrolases involved in the degradation of G(M2) ganglioside and related metabolites. Currently, there is no viable treatment for the disease. Here, we show that adenovirus-mediated transfer of the beta-subunit of beta-hexosaminidase restored Hex A and Hex B activity after infection of Sandhoff fibroblasts. Gene transfer following intracerebral injection in a murine model of Sandhoff disease resulted in near-normal level of enzymatic activity in the entire brain at the different doses tested. The addition of hyperosmotic concentrations of mannitol to the adenoviral vector resulted in an enhancement of vector diffusion in the injected hemisphere. Adenoviral-induced lesions were found in brains injected with a high dose of the vector, but were not detected in brains injected with 100-fold lower doses, even in the presence of mannitol. Our data underline the advantage of the adjunction of mannitol to low doses of the adenoviral vector, allowing a high and diffuse transduction efficiency without viral cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960974     DOI: 10.1038/sj.gt.3302081

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  Efficient CNS gene delivery by intravenous injection.

Authors:  Jean-Pierre Louboutin; Alena A Chekmasova; Elena Marusich; J Roy Chowdhury; David S Strayer
Journal:  Nat Methods       Date:  2010-10-17       Impact factor: 28.547

2.  Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles.

Authors:  Keith B Neeves; Andrew J Sawyer; Conor P Foley; W Mark Saltzman; William L Olbricht
Journal:  Brain Res       Date:  2007-08-29       Impact factor: 3.252

3.  Effective gene therapy in an authentic model of Tay-Sachs-related diseases.

Authors:  M Begoña Cachón-González; Susan Z Wang; Andrew Lynch; Robin Ziegler; Seng H Cheng; Timothy M Cox
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

4.  Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone.

Authors:  Ester J Kwon; Jurate Lasiene; Berit E Jacobson; In-Kyu Park; Philip J Horner; Suzie H Pun
Journal:  Biomaterials       Date:  2009-12-09       Impact factor: 12.479

5.  Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.

Authors:  Subha Karumuthil-Melethil; Sahana Nagabhushan Kalburgi; Patrick Thompson; Michael Tropak; Michael D Kaytor; John G Keimel; Brian L Mark; Don Mahuran; Jagdeep S Walia; Steven J Gray
Journal:  Hum Gene Ther       Date:  2016-07       Impact factor: 5.695

Review 6.  CNS-directed gene therapy for lysosomal storage diseases.

Authors:  Mark S Sands; Mark E Haskins
Journal:  Acta Paediatr       Date:  2008-04       Impact factor: 2.299

7.  Early deficits in motor coordination and cognitive dysfunction in a mouse model of the neurodegenerative lysosomal storage disorder, Sandhoff disease.

Authors:  Maria Gulinello; Fengying Chen; Kostantin Dobrenis
Journal:  Behav Brain Res       Date:  2008-06-20       Impact factor: 3.332

Review 8.  Animal models of GM2 gangliosidosis: utility and limitations.

Authors:  Cheryl A Lawson; Douglas R Martin
Journal:  Appl Clin Genet       Date:  2016-07-20

9.  Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model.

Authors:  Evan Woodley; Karlaina J L Osmon; Patrick Thompson; Christopher Richmond; Zhilin Chen; Steven J Gray; Jagdeep S Walia
Journal:  Mol Ther Methods Clin Dev       Date:  2018-10-26       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.